AI assistant
GILEAD SCIENCES, INC. — Director's Dealing 2014
Sep 30, 2014
29828_dirs_2014-09-30_5a13cecd-1932-4131-9630-9ed735cdfc93.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2014-09-26
Reporting Person: Carter Paul Rutherford (EVP Commercial Ops)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-09-26 | Common Stock | M | 2000 | $40.56 | Acquired | 34244 | Direct |
| 2014-09-26 | Common Stock | S | 2000 | $107.4725 | Disposed | 32244 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-09-26 | Non-Qualified Stock Option (right to buy) | $40.56 | M | 2000 | Disposed | 2023-02-01 | Common Stock (2000) | Direct |
Footnotes
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3: Sale prices reported for the transactions reported here range from $107.47 to $107.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.